Pantoprazolo Abc (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazolo Abc, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed to treat acid‑related gastrointestinal conditions such as gastro‑oesophageal reflux disease, erosive oesophagitis and peptic ulcer disease in adult patients.

GNH USA supplies Pantoprazolo Abc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Pantoprazolo Abc (pantoprazole) acts on the gastric proton pump to lower acid production in several acid‑related disorders.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing gastric acidity. - Erosive oesophagitis: promotes healing of inflamed esophageal lining. - Peptic ulcer disease: supports ulcer closure and prevents recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion in this rare endocrine disorder.

Pantoprazolo Abc may be associated with a range of adverse reactions, which are categorised by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools occurring during treatment. - Nausea: sensation of unease in the stomach. - Abdominal pain: discomfort or cramps in the abdomen. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Clostridioides difficile infection: severe colitis with watery diarrhea. - Hypomagnesemia: low blood magnesium levels with prolonged use. - Liver enzyme elevation: increased ALT or AST indicating hepatic stress. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare severe skin reactions.

Before initiating Pantoprazolo Abc, certain precautions should be considered to ensure safe use.

- Assess renal function: dose adjustment may be required in severe renal impairment. - Monitor magnesium levels: prolonged therapy can lead to hypomagnesemia. - Review concomitant CYP2C19 inhibitors: may increase pantoprazole exposure. - Use cautiously in hepatic disease: drug is metabolised in the liver. - Store at room temperature: keep in the original packaging, protect from moisture.

Pantoprazolo Abc can affect, or be affected by, several medicines; interactions are classified by their clinical significance.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect when co‑administered. - Atazanavir: decreased absorption of atazanavir, lowering its efficacy. - High‑dose methotrexate: increased methotrexate toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer monitoring. - Digoxin: may raise serum digoxin concentrations. - Diazepam: potential increase in plasma levels.